Barry J. Simon, M.D.
President & Chief Administrative Officer
Dr. Simon has served as the Company’s President and CEO from 2007 to 2015, as its President and COO since 2015 and presently serves as its President and CAO and as a Director. Dr. Simon also presently serves as the Chairman of the Board for Cue BioPharma (NASDAQ: CUE) and as Director for Viracta Therapeutics. Previously, Dr. Simon held Vice President, senior level and advisory positions at F. Hoffmann-La Roche (VTX: ROG), Roche Labs, Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol, NorthSound Capital, LLC, and HealthPro BioVentures. Dr. Simon has broad experience in the public and private settings, having led product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, as well as commercial product launches, IND & BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on products launches including Xeloda®, Pegasys®, Fortovase®, Tamiflu®, Camptobell®, Boniva®, Fuzeon®, Valcyt®, and Accutane®. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. Dr. Simon trained clinically in Infectious Diseases, Anesthesiology and Internal Medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.